DEVELOPMENT AND VALIDATION OF THE METHOD FOR DETERMINATION OF RELATED IMPURITIES IN RIBOXIN TABLETS

M.V. Rosada, N.Yu. Bevz, V.A. Georgiyants
National University of Pharmacy
53, Pushkinska Str., 61002, Kharkiv. E-mail: rosada@list.ru

Key words: standardization; Riboxin; tablets; related impurities; HPLC

Riboxin (inosine) is used in medicine for treating cardiovascular diseases, so the number of dosage forms containing this substance as an active ingredient is constantly increasing at the Ukrainian pharmaceutical market. When developing quality control methods for a dosage form containing one active substance it is advisable to carry out tests on the presence of related impurities besides identification and assay tests. The article presents the data concerning development of the method for determination of related impurities (hypoxanthine, guanosine) in riboxin tablets using HPLC. The analysis was carried out using a HPLC column (125×4 mm i.d., 5 μm particles) filled with "Lichrospher 60 RP select B" sorbent. The mobile phase adjusted with the phosphate buffer to pH 3.5 was used. The UV detection was performed at 250 nm. The validation characteristics have been studied using the acceptance criteria for the tolerances of the content not more than 0.5% for each impurity, and they confirm specificity (the absence of the effect of excipients), linearity, precision (convergence), accuracy ($\Delta z = 0.79 \leq \max \Delta z = 5.0$, $\delta = 0.21 \leq \max \delta = 0.26$, $a = 0.48$, $r = 0.99997 > 0.9976$ for hypoxanthine, and $\Delta z = 0.83 \leq \max \Delta z = 5.0$, $\delta = 0.17 \leq \max \delta = 0.28$, $a = 0.21$, $r = 0.99997 > 0.9976$ for guanosine), and the application range for the method proposed.
Riboxin is used for improvement of the functional recovery after cranio-cerebral traumas; it affects restoration of the level of the associated protein GAP-43 growth in the hippocampus [1], and has good indications for treating patients suffered a stroke [2]. Recently, a lot of dosage forms containing riboxin appear at the domestic pharmaceutical market. The State Pharmacopoeia of Ukraine (SPhU) recommends to determine related impurities both in dosage forms and in substances.

The inosine substance is obtained by microbiological synthesis, and hypoxanthine and guanosine can be by-products of this synthesis [3]. Their certain amount (not more than 0.5%) is regulated in the substance [4, 5, 6]. For the further substantiation for either inclusion or exclusion of impurities in the specification it is advisable to determine these related impurities in the finished dosage form.

Nowadays, there are three requirements for drug substances and medicines: efficacy, safety, and quality. Recently, in drug quality control the attention is paid to determination of related impurities [7, 8, 9], which may have a significant impact on the human health due to potential teratogenic, mutagenic or carcinogenic effects. Therefore, control and monitoring of impurities is a pressing question when developing and producing drugs. In accordance with the Pharmacopoeia of the People’s Republic of China [5], the manufacturer [4] and the State Pharmacopoeia of the Russian Federation [6] the HPLC method is used for the assay of riboxin and determination of related impurities. The equipment change and technological peculiarities of tablet production need improvement of the existing method or development of the new one.

The aim of our research was to develop the method for determination of related impurities in riboxin tablets by HPLC, and validate it in accordance with the SPhU requirements to drugs in the form of tablets [10, 11, 12].

Fig. 1. The chromatogram of the placebo solution.

Fig. 2. The chromatogram of the chromatographic system suitability.

The study object was "Riboxin" tablets with the content of 200 mg of the active substance (excipients – potato starch, sugar, hypromellose, sodium croscarmellose, povidone K25 and magnesium stearate). The reference samples of 9-β-D-ribofuranosyl hypoxanthine (riboxin (inosine), batch 1 from 20.04.2012 (RS, SPhU)); guanine-9-β-hypoxanthine (guanosine), batch 0B006736 from 09.08.2010; 6-hydroxypurine (hypoxanthine), batch 0L006460 from 09.07.2010 were used. Analytical studies were performed by the HPLC method on an Agilent 1200 chromatograph ("Agilent Technologies", Germany) using OHAUS AP 250D laboratory balances ("Ohaus Corporation", USA), and the measuring glassware of class A.

Determination of related impurities of riboxin in tablets was carried out by the HPLC method. To determine related impurities in the test solution the diluted solution of riboxin impurities was used as the reference solution. Since the method for determination of related impurities must be validated according to the SPhU requirements, the main validation characteristics were studied: specificity, linearity, precision (convergence), accuracy, and the application range.

The tolerances of the content of related impurities of riboxin in the finished dosage form is not more than 0.5%. Therefore, during validation the parameters for \( B = 0.5\% \), i.e. the maximum uncertainty of the analysis \( (\Delta_{\text{ref}}) \) must be not more than 5.0%, were the evaluation criteria of this method [8, 13, 14, 15].

The specificity of the method is confirmed by the absence of the effect of excipients. The chromatogram of the placebo solution shows it (Fig. 1).

The suitability of the chromatographic system is performed since the peaks of related substances (hypoxanthine and guanosine) and the peak of the basic substance (riboxin) are completely separated (Fig. 2).

The linearity, precision, accuracy, and the application range of the given method were determined on the model mixtures with the known content of related impurities in the range from 25% to 125% relative to the maximum permissible value. Both the reference solution and model solutions were prepared according to the same method; the actual values \( X_i \) from the ratio of \( X = \frac{S_i}{S_{\text{st}}}, \text{100\%} \) were equal in relation to the actual weights of the riboxin substance taken for preparation of the model solution and the
reference solution. The working concentration of the test solution and the reference solution was approximately 10 μg/ml. The linearity of dependence of the peak areas of hypoxanthine and guanosine solutions on the concentration in the range of approximately 2.5 μg/ml to 12.5 μg/ml was determined. The linear dependence of the peak area on the concentration of related impurities of hypoxanthine and guanosine in the normalized coordinates is presented in Fig. 3 and Fig. 4, respectively.

Calculation of parameters of the linear dependence \( Y_i = b \times X_i + a \) for related impurities of riboxin (hypoxanthine and guanosine) was performed by the least squares method (Tab. 1).

As can be seen from Table 1, all requirements for the linear dependence parameters are met, i.e. the linearity of the method for determination of related impurities is confirmed within the whole range of concentrations (25-125%). The high value of the correlation coefficient also meets the requirements of the acceptance criteria \( r = 0.9976 \) and confirms the linearity of dependence between the "introduced" and "found" amount of the substance.

The data of Tab. 2 and 3 show that for both hypoxanthine and guanosine the method of analysis is characterized by sufficient precision (convergence). The value of the relative confidence interval of value \( Z \) found is less than the critical value for convergence of results (5.00%).

The tests for the tablets studied showed that in the chromatograms of the test solution for "Riboxin" drug only one impurity (guanosine) in the amount of approximately 0.12% was determined (Fig. 5).

Therefore, it has been found that the amount of related impurities in "Riboxin" tablets does not increase compared to the riboxin substance, i.e. the impurity identified is the technological impurity of the substance.

| Hypoxanthine | b     | \( S_b \) | a     | \( S_a \) | \( S_r \) | \( r \) |
|--------------|-------|-----------|-------|-----------|-----------|-------|
|              | 0.9925 | 0.0028    | 0.4834 | 0.2252    | 0.3028    | 0.99997 |
| Criteria     |       |           |       |           |           |       |
|              | \(<1.8946^*\) | 0.2252 = 0.43 | <2.1 | \( >0.9976 \) |
| Guanosine    | 0.9941 | 0.0027    | 0.2110 | 0.2191    | 0.2946    | 0.99997 |
| Criteria     |       |           |       |           |           |       |
|              | \(<1.8946^*\) | 0.2191 = 0.42 | <2.1 | \( >0.9976 \) |

Fig. 3. The linear dependence of the peak area on the hypoxanthine concentration.

Fig. 4. The linear dependence of the peak area on the guanosine concentration.

Fig. 5. The chromatogram of the test solution.
The results of analysis of the model mixtures and their statistical processing for hypoxanthine determination

| No. of the model solution | The sample weight of hypoxanthine RS, mg $m_a = 9.9$ mg | Found in % to the introduced $(X_i = C_i/C_{int} \%)$ | The area mean values $(S_i)$ $(S_{int} = 259.80)$ | Found in % to the concentration of the reference solution $(Y_i = S_i/S_{int} \%)$ | Found in % to the introduced $Z_i = 100(Y/Y_i) \%$ |
|---------------------------|--------------------------------------------------------|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 1                         | 2.5                                                     | 25.25                                           | 66.50                                         | 25.60                                         | 101.39                                        |
| 2                         | 2.5                                                     | 25.25                                           | 66.50                                         | 25.60                                         | 101.39                                        |
| 3                         | 5.0                                                     | 50.51                                           | 131.50                                        | 50.62                                         | 100.22                                        |
| 4                         | 5.0                                                     | 50.51                                           | 132.10                                        | 50.85                                         | 100.67                                        |
| 5                         | 7.5                                                     | 75.76                                           | 195.90                                        | 75.40                                         | 99.52                                         |
| 6                         | 7.5                                                     | 75.76                                           | 196.50                                        | 75.64                                         | 99.84                                         |
| 7                         | 10.0                                                    | 101.01                                          | 260.20                                        | 100.15                                        | 99.15                                         |
| 8                         | 12.5                                                    | 126.26                                          | 327.80                                        | 126.17                                        | 99.93                                         |
| 9                         | 12.5                                                    | 126.26                                          | 327.20                                        | 125.94                                        | 99.75                                         |

Mean, % 99.59

Relative standard deviation, RSDz,%

$$RSD_z(\%) = \frac{\sqrt{\sum (Z_i - \bar{Z})^2}}{n - 1} \times 100$$

$0.34$

Relative confidence interval,

$$\Delta_z(\%) = t(95, n - 1) \times RSD_z = 1.860 \times RSD_z, \%$$

$0.79$

Critical value for convergence of results $\Delta_{int} \%$ (limit uncertainty) 5.0

$5.0$

Systematic error $\delta = |Z - 100|$ 0.21

Criterion of the systematic error insignificance

$$\delta(\%) = \frac{\Delta_z}{\sqrt{n}} = \frac{0.7924}{3} = 0.26 (0.21 \leq 0.26 \text{ if not satisfied 1),}}$$

then $\delta \leq 0.32 \times 5.0 = 1.6\% (0.26 \leq 1.6)$. Is not satisfied

Satisfied

The overall conclusion of the method Correct

Experimental Part

The method for determination of related impurities: Test solution. Place approximately 68.7 mg (accurate weight) of the powdered tablets into a 250 ml flask, add 150 ml of water, stir the solution obtained for 10-15 min, or place in an ultrasonic bath for 10 min, and cool. Then dilute the solution to the volume with the same solvent, mix, and filter through a 0.45 microns membrane filter rejecting the first 5 ml of the filtrate.

Reference solution (a). Place 10.0 mg of guanosine into a 100 ml flask, dissolve in warm water, cool, dilute the solution obtained to the volume with the same solvent, and mix.

Reference solution (b). Place 10.0 mg of hypoxanthine into a 100 ml flask, dissolve in warm water, cool, dilute the solution obtained to the volume with the same solvent, and mix.

Reference solution (c). Place 1.0 ml of the Reference solution (a) and 1.0 ml of the Reference solution (b) into a 100 ml flask, dilute the solution obtained to the volume with water, and mix.

Reference solution (d). Place 20.0 mg of riboxin into a 100 ml flask, dissolve in water, dilute the solution obtained to the volume with the same solvent, and mix.

Reference solution (e). Mix the Reference solution (c) with the Reference solution (d).

Chromatography is carried out in the conditions described below:

- Column – 125×4 mm i.d., filled with “Lichrospher 60 RP select B” sorbent (5 μm particles) or similar, for which the requirements of the Chromatographic system suitability” test are met;
- The flow rate of the mobile phase – 0.2 ml/min;
- Detection – at the wavelength of 250 nm;
- Column temperature – 35°C.

For chromatography 20 μl of the Test solution, the Reference solution (c) and the Reference solution (e) were used, at least 3 chromatograms should be obtained.
The system suitability test: The chromatography system is considered to be suitable if the following conditions are performed:

- resolution of hypoxanthine and riboxin should be at least 4.0;
- resolution of guanosine and riboxin should be at least 2.0.

Preparation of the mobile phase:
Place 4.80 g of potassium dihydrogen phosphate, 0.24 g of sodium heptanesulfonate into a 1000 ml flask, dissolve in 700 ml of water, add 0.20 g of triethylamine and 20 ml of methanol, and mix the solution obtained. Then, adjust pH to 3.5 with the concentrated phosphoric acid by potentiometry. Dilute the solution obtained to the volume of 1000 ml with water and mix.

Conclusions

1. The method for determination of related impurities has been developed; its suitability has been proven by the HPLC method.
2. The validation study for the "Related impurities" test performed confirms the compliance of such characteristics as specificity, linearity, precision (convergence), accuracy, and the application range with the acceptance criteria.

References

1. Shlomit Dachir, Dalia Shabashov, Victoria Trembovler, Alexander G. Alexandrovich, Larry I. Benowitz, Esther Shohami. Inosine improves functional recovery after experimental traumatic brain injury. Brain Research, 2014, No.1555, pp.78-88.
2. Laila Zai, Christina Ferrari, Carlie Dice, Sathish Subbaiah, Leif A. Havton, Giovanni Coppola, Daniel Geschwind, Nina Irwin, Eric Huebner, Stephen M. Strittmatter, Larry I. Benowitz. Inosine Augments the Effects of a Nogo Receptor Blocker and of Environmental Enrichment to Restore Skilled Forelimb Use after Stroke. Journal of Neuroscience, 2011, No.31, pp.5977-5988.
3. Пат. РФ 1755583 (1994). Заявл.: 31.10.1990. Опубл. 30.08.1994 [Электронный ресурс] Режим доступа http://patents.su/0-1755583-sposob-polucheniya-inozina.html.
4. Drug master file (for Inosine). “Starlake Bioscience Co.”, China, 2007, p.68.
5. Китайская фармакопея. Т. 2. People’s Medical Publishing House, 2005, pp.438-440.
6. Государственная фармакопея Российской Федерации Ч. 1. Научный центр экспертизы средств медицинского применения. РИБОКСИН (ФС 42-0275-07), 2007, с.624-627.

Table 3

The results of analysis of the model mixtures and their statistical processing for guanosine determination

| No. of the model solution | The sample weight of guanosine RS, mg \(m_s = 9.9\ mg\) | Found in % to the introduced \(X_i = C_i/C_m, \%\) | The area mean values \(S_i = 147.70\) | Found in % to the concentration of the reference solution \(Y_i = S_i/S_m, \%\) | Found in % to the introduced \(Z_i = 100(Y_i/X_i)\) % |
|--------------------------|----------------------------------------------------------|---------------------------------|-------------------------------|---------------------------------|------------------------|
| 1                        | 2.5                                                      | 25.25                           | 37.30                         | 25.25                           | 100.00                 |
| 2                        | 2.5                                                      | 25.25                           | 37.50                         | 25.39                           | 100.55                 |
| 3                        | 5.0                                                      | 50.51                           | 74.70                         | 50.58                           | 100.14                 |
| 4                        | 5.0                                                      | 50.51                           | 74.70                         | 50.58                           | 100.14                 |
| 5                        | 7.5                                                      | 75.76                           | 111.40                        | 75.42                           | 99.55                  |
| 6                        | 7.5                                                      | 75.76                           | 111.40                        | 75.42                           | 99.55                  |
| 7                        | 10.0                                                     | 101.01                          | 147.70                        | 100.00                          | 99.00                  |
| 8                        | 12.5                                                     | 126.26                          | 185.90                        | 125.86                          | 99.68                  |
| 9                        | 12.5                                                     | 126.26                          | 186.20                        | 126.07                          | 99.85                  |

| Mean, %                    | 99.83 |
| Relative standard deviation, RSDz, % | 0.45 |
| Relative confidence interval, \(\Delta_z = \frac{t(95,n – 1)×RSD_z}{\sqrt{n}}\) % | 0.83 |
| Critical value for convergence of results \(\Delta_{w_%} \) % (limit uncertainty) 5.0 | 5.0 |
| Systematic error \(\delta = |Z – 100|\) % | 0.17 |

*Criterion of the systematic error insignificance*  
\[ s % = \frac{\Delta z}{\sqrt{n}} = \Delta z \frac{3}{3} = 0.8337 \frac{3}{3} = 0.28 \ (0.17 \leq 0.28 \text{ if not satisfied 1}), \]
then \(\delta \leq 0.32 \times 5.0 = 1.6\% \ (0.28 \leq 1.6)\) Satisfied

*The overall conclusion of the method* Correct

The overall conclusion of the method: Correct
7. Александров А. В. Вызовы и возможности документа ICH Q10 «Фармацевтическая система качества». Промышленное обозрение, 2008, №4(9), с.19-21.
8. FDA / Guidance for Industry-ANDAs: Impurities in Drug Products. Rockville, MD, 2010, p.7.
9. Jiben Roy. Pharmaceutical Impurities – A Mini-Review. AAPS Pharm. Sci. Tech., 2002, Vol. 3(2), p.7.
10. Гризодуб А. И. Стандартные процедуры валидации методик контроля качества лекарственных средств. Фармаком, 2006, №1/2, с.3-44.
11. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Х.: РІРЕГ, 2001, 556 с.
12. Настанова «Лікарські засоби. Фармацевтична розробка» (Настанова 42-3.1:2004). К.: МОРНО, 2004, 15 с.
13. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Доп. 1. Х.: РІРЕГ, 2004, 494 с.
14. Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». 1-е вид. Доп. 2. Х.: РІРЕГ, 2008, 617 с.
15. Стандартизованная процедура валидации методик контроля содержания примесей в готовых лекарственных средствах методом жидкостной хроматографии / А. И. Гризодуб, Д. А. Леонтьев, Т. И. Доценко, В. А. Загорий. Фармаком, 2005, №2-3, с.78-94.

Надійшла до редакції 12.10.2015 р.